Handok to exclusively market Abbott’s hyperlipidemia drug in Korea

Handok said it began the local sales of Lipidil (ingredient: fenofibrate), Abbott’s hyperlipidemia treatment, on Wednesday. An agreement between the two companies gave Handok exclusive rights to distribute, sell, and promote two Lipidil products -- Lipidil Supra and Lipidil NT – in Korea.

Lipidil, which contains fenofibrate as its active ingredient, is a widely prescribed fibrate-based hyperlipidemia treatment in both global and Korean markets. Lipidil Supra is the original fenofibrate product developed by Abbott, while Lipidil NT, reimbursed from January 2023, offers the convenience of administration regardless of meals.

"Leveraging our success in the diabetes business, Handok is expanding its competitiveness into hypertension and hyperlipidemia,” Handok’s Senior Vice President Kim Yoon-mi at ETC division said. “By introducing Lipidil, we are broadening our product portfolio in the chronic disease sector, enabling us to provide comprehensive treatment solutions while strengthening our leadership in this market through synergies with our existing products."

With the addition of Lipidil to its portfolio, Handok further aims to solidify its position in the chronic disease treatment market, expanding its expertise from diabetes and hypertension to hyperlipidemia.

Handok has been continuously expanding its pipeline in the chronic disease field. The company has been marketing treatments in the diabetes market as Amaryl, Tenelia, and Lantus, as well as blood glucose monitoring devices like Barozen. In 2024, Handok co-developed and launched Aprovasc, a hypertension treatment, with Sanofi, and expanded its partnership with the company by co-marketing Sanofi’s Aprovel and CoAprovel.